NantHealth Inc - NH STOCK NEWS

NantHealth (NASDAQ: NH) has partnered with Intraprise Health to enhance HIPAA compliance solutions for healthcare providers. This collaboration will integrate Intraprise Health’s HIPAA One Security Risk Assessment software into NantHealth’s NaviNet platform. Over 64,000 providers utilize Intraprise Health’s software, which offers automated compliance gap assessments and tracking. The partnership aims to simplify compliance with evolving regulations, benefiting healthcare practices by ensuring patient data security.

NantHealth, Inc. (NASDAQ-GS: NH) reported its Q2 2021 financial results, showing total net revenue of $16.1 million, a decrease from $17.6 million in Q2 2020. Gross profit was $9.1 million, representing 56% of revenue, down from 58% year-over-year. The company recorded a net loss of $15.3 million ($0.13 per share), significantly reduced from a loss of $48.3 million ($0.44 per share) in the same quarter last year. Cash reserves improved to $52 million following a $137.5 million financing transaction in April, enabling ongoing investments in product enhancements and capabilities.

NantHealth (NASDAQ: NH) has appointed Dr. Tiffany Avery as the new Chief Medical Officer, effective immediately. Dr. Avery's role will focus on providing clinical strategic direction and enhancing NantHealth’s Eviti decision support platform. With a strong background in oncology and epidemiology, she aims to improve health outcomes and address health disparities. Dr. Avery has been part of NantHealth since 2019, previously working in oncology at prominent institutions. Her expertise in cancer prevention and treatment will support the company's mission of delivering equitable healthcare.

NantHealth, Inc. (NASDAQ-GS: NH) will report its financial results for Q2 2021 on August 5, 2021, after market close. The management will host a conference call at 1:30 p.m. PT to discuss the company's performance. Interested parties can access the conference call by dialing 800-582-4096 (U.S./Canada) or 212-231-2918 (international). The call will also be broadcasted live on the NantHealth website.

NantHealth, Inc. (NASDAQ-GS: NH) reported first-quarter financial results for 2021, highlighting a revenue decline to $16.2 million from $18.2 million in Q1 2020. The company completed a $137.5 million financing to retire existing convertible notes and support growth in SaaS offerings and data services. R&D expenses increased to $5 million, contributing to a net loss of $15.4 million, or $0.14 per share. The launch of Eviti Connect for autoimmune diseases and expansion of OpenNMS offerings are key initiatives, aiming to broaden their business scope beyond healthcare.

NantHealth, a provider of enterprise solutions, has launched Eviti Connect for autoimmune diseases, a tool designed to help payers and providers manage treatment costs effectively. This expansion aims to benefit the approximately 50 million people in the U.S. living with autoimmune diseases, with annual treatment costs around $100 billion. Eviti Connect has previously supported over 345,000 cancer patients, yielding substantial savings for payers. The new platform is expected to streamline authorization workflows and enhance treatment decision-making in complex healthcare scenarios.

NantHealth, Inc. (NASDAQ-GS: NH) is set to release its financial results for Q1 2021 on May 6, 2021, after market close. The management will conduct a conference call at 1:30 p.m. PT (4:30 p.m. ET) to discuss performance details. Interested parties can join the call via phone or listen online at nanthealth.com.

NantHealth specializes in enterprise solutions for transforming complex data into actionable insights across various sectors, including healthcare and logistics.

NantHealth announced a financing deal involving the issuance of $137.5 million in senior unsecured convertible notes due 2026, aimed at enhancing financial flexibility and funding growth initiatives. The proceeds will retire existing convertible notes and support investments in businesses like NaviNet and Eviti, as well as the OpenNMS subsidiary. The deal is backed by existing investors Highbridge Capital and Nant Capital, with expected closing on or before April 27, 2021. The notes carry a 4.5% interest rate, paid semiannually, unless converted to stock.

NantHealth (NASDAQ: NH) has launched a new population health management product designed to aggregate disparate data for a holistic view of patient care. This solution aims to enhance workflow efficiency among providers, payers, and patients while reducing unnecessary costs. With the trend towards value-based care, the product enables better healthcare delivery by leveraging historical data and advanced analytics. According to the American Hospital Association, many providers are already engaging in alternative payment models, indicating the relevance of NantHealth's offering in current healthcare dynamics.